Vast Therapeutics

Home
United States
Morrisville, NC
Vast Therapeutics

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Vast Therapeutics, Pharmaceutical Company, 615 Davis Drive, Morrisville, NC.

11/19/2025

We’ve successfully completed the Single Ascending Dose (SAD) portion of our Phase 1 study for our lead candidate, ALX1, an inhaled, nebulized pro-drug designed to deliver nitric oxide directly to the lungs. At all four dose levels in healthy adults, ALX1 was well tolerated with no serious adverse events.

This milestone paves the way for our next steps: the Multiple Ascending Dose (MAD) portion is already underway, and we’re aiming to initiate our Phase 2 study in patients during H1 2026.

We’re incredibly proud of the team, our participants, and our mission: to transform treatment for chronic lung diseases like bronchiectasis, cystic fibrosis, and beyond.

Read the full release here: https://www.vasttherapeutics.com/vast-therapeutics-completes-first-milestone-in-phase-1-clinical-program/

09/23/2025

Non-tuberculous mycobacteria (NTM) are naturally occurring bacteria found in soil and water. For many, they pose little risk, but for those living with chronic lung diseases, NTM can cause serious and persistent infections that impact quality of life.

09/19/2025

Ella Belasa has been battling Pseudomonas her entire life. We believe it's going to take multiple therapies and great scientific strides to win the battle for those living with rare lung disease. Watch the interview here: https://youtu.be/pGX1krKTnqM?si=7qAnHi3DJT6erPSB

09/17/2025

Vast Therapeutics has been awarded a second $2 million grant to accelerate our efforts in combating rare respiratory diseases.

This funding supports the development of groundbreaking therapies designed to bring hope to patients and families affected by these challenging conditions.

We’re grateful for the recognition and support of our work, and excited to continue advancing the science of respiratory health.

Read the full press release here: https://www.vasttherapeutics.com/vast-awarded-another-2-million-grant-to-combat-rare-respiratory-disease/

09/11/2025

Pseudomonas is one of the leading causes of serious issues for those living with chronic lung disease. Watch the full interview with Ella Belasa and how she perseveres despite the difficulties that Cystic Fibrosis presents. https://youtu.be/pGX1krKTnqM?si=7qAnHi3DJT6erPSB

08/01/2025

We're thrilled to report that not long after our interview with Amber Harris on our Rare and Real series, she received her new lungs!

She went in for the transplant surgery less than a week after our conversation, and she is recovering very well, surrounded by her amazing support system of friends and family.
Please join us in wishing Amber continued recovery and lifelong health and happiness!

07/17/2025

Imagine struggling to breathe for decades, with no name for what you’re living through. That was the reality for Amber Harris, who lived 44 years before finally being diagnosed with Primary Ciliary Dyskinesia (PCD).

PCD is a rare, often misunderstood lung condition that can go undiagnosed for years, sometimes decades, leaving patients vulnerable to chronic infections and lung damage.

This story isn’t just personal, it’s a wake-up call for awareness, research and innovation.

At Vast Therapeutics, we’re developing solutions that go beyond managing symptoms. We’re committed to targeting the root causes of lung infections, including Pseudomonas aeruginosa, which disproportionately affects those with PCD, cystic fibrosis, and other rare lung conditions.

07/16/2025

We’re thrilled to share that the FDA has granted orphan drug designation to the active pharmaceutical ingredient used in our investigational ALX1 drug product for the treatment of respiratory infections in patients with cystic fibrosis (CF).

Why it matters:
• Targeted innovation: ALX1 is designed to restore nitric oxide levels in the lungs, minimizing the infection–inflammation cycle that so often burdens CF patients
• Focused on need: Respiratory infections remain a leading cause of decline in CF patients—Orphan status highlights the urgent need for new therapies.

To find out more click here: https://www.vasttherapeutics.com/vasts-lead-drug-candidate-receives-orphan-drug-designation-for-the-treatment-of-respiratory-infection-in-patients-with-cystic-fibrosis/

07/15/2025

What is Primary Ciliary Dyskinesia (PCD)?

Cilia are tiny, hair-like structures found throughout the body, especially in the lungs, sinuses, ears, and reproductive system. Their job is to move mucus, bacteria, and other particles out of airways to keep the body healthy.

In people with Primary Ciliary Dyskinesia (PCD), these cilia are missing, misshapen, or unable to move properly. This leads to a dangerous buildup of mucus, which can cause chronic respiratory infections, including from difficult pathogens like Pseudomonas aeruginosa.

We're driven by the belief that everyone deserves to breathe freely. That’s why we’re developing innovative therapies aimed at fighting resistant infections like Pseudomonas, and helping people with rare lung diseases like PCD live longer, healthier lives.

Address

615 Davis Drive
Morrisville, NC
27560

Website

http://www.vasttherapeutics.com/

Alerts

Be the first to know and let us send you an email when Vast Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Morrisville?